Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2013

01-06-2013 | Research Article

The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells

Authors: Yang Liu, Liang Wang, Xu-Yong Lin, Jian Wang, Juan-Han Yu, Yuan Miao, En-Hua Wang

Published in: Tumor Biology | Issue 3/2013

Login to get access

Abstract

The objective of the current study was to investigate the expression pattern and clinicopathological significance of differentiated embryo–chondrocyte-expressed gene 1 (DEC1) in patients with non-small-cell lung cancer (NSCLC). In 118 archived NSCLC tissues, the positive rate of DEC1 was reduced in human lung cancer samples (36/118, 30.5 %) compared with adjacent normal lung tissues (106/118, 89.8 %), as measured by immunohistochemical staining. Loss of DEC1 was correlated with poor differentiation (p = 0.005) and high p-TNM stage (p = 0.002). Consistently, downregulation of DEC1 by siRNA knockdown promoted the growth and colony formation in the A549 lung cancer cell line, and overexpression of DEC1 inhibited the growth and colony formation in the BE1 lung cancer cell line. In addition, a significant negative correlation was found between DEC1 and cyclin D1 (p = 0.014) in 118 cases of NSCLC. Knockdown of DEC1 resulted in the upregulation of cyclin D1, and overexpression of DEC1 led to the downregulation of cyclin D1. Together with the observation that DEC1 bound directly to the promoter region of cyclin D1 in A549 cells, these results indicate that loss of DEC1 may promote tumor progression in NSCLC through upregulation of cyclin D1, and DEC1 might serve as a novel therapeutic target of NSCLC.
Literature
1.
2.
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small cell lung cancer collaborative group. BMJ 1995;311:899–909
3.
O'Mahony D, Kummar S, Gutierrez ME. Non-small-cell lung cancer vaccine therapy: a concise review. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:9022–8.CrossRef
4.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.PubMedCrossRef
5.
Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–44.PubMedCrossRef
6.
Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res. 2006;66:9736–43.PubMedCrossRef
7.
Boudjelal M, Taneja R, Matsubara S, Bouillet P, Dolle P, Chambon P. Overexpression of stra13, a novel retinoic acid-inducible gene of the basic helix–loop–helix family, inhibits mesodermal and promotes neuronal differentiation of p19 cells. Genes Dev. 1997;11:2052–65.PubMedCrossRef
8.
Shen M, Kawamoto T, Yan W, Nakamasu K, Tamagami M, Koyano Y, et al. Molecular characterization of the novel basic helix–loop–helix protein DEC1 expressed in differentiated human embryo chondrocytes. Biochem Biophys Res Commun. 1997;236:294–8.PubMedCrossRef
9.
Guillaumond F, Lacoche S, Dulong S, Grechez-Cassiau A, Filipski E, Li XM, et al. Altered STRA13 and DEC2 circadian gene expression in hypoxic cells. Biochem Biophys Res Commun. 2008;369:1184–9.PubMedCrossRef
10.
Qian Y, Zhang J, Yan B, Chen X. Dec1, a basic helix–loop–helix transcription factor and a novel target gene of the p53 family, mediates p53-dependent premature senescence. J Biol Chem. 2008;283:2896–905.PubMedCrossRef
11.
Yamada K, Miyamoto K. Basic helix–loop–helix transcription factors, bhlhb2 and bhlhb3; their gene expressions are regulated by multiple extracellular stimuli. Frontiers in bioscience. A J virtual Libr. 2005;10:3151–71.CrossRef
12.
Ivanova A, Liao SY, Lerman MI, Ivanov S, Stanbridge EJ. Stra13 expression and subcellular localisation in normal and tumour tissues: implications for use as a diagnostic and differentiation marker. J Med Genet. 2005;42:565–76.PubMedCrossRef
13.
Turley H, Wykoff CC, Troup S, Watson PH, Gatter KC, Harris AL. The hypoxia-regulated transcription factor dec1 (stra13, sharp-2) and its expression in human tissues and tumours. J Pathol. 2004;203:808–13.PubMedCrossRef
14.
Chakrabarti J, Turley H, Campo L, Han C, Harris AL, Gatter KC, et al. The transcription factor dec1 (stra13, sharp2) is associated with the hypoxic response and high tumour grade in human breast cancers. Br J Cancer. 2004;91:954–8.PubMedCrossRef
15.
Zheng Y, Jia Y, Wang Y, Wang M, Li B, Shi X, et al. The hypoxia-regulated transcription factor dec1 (stra13, sharp-2) and its expression in gastric cancer. Omics A J Genet Biol. 2009;13:301–6.CrossRef
16.
Li Y, Zhang H, Xie M, Hu M, Ge S, Yang D, et al. Abundant expression of dec1/stra13/sharp2 in colon carcinoma: its antagonizing role in serum deprivation-induced apoptosis and selective inhibition of procaspase activation. Biochem J. 2002;367:413–22.PubMedCrossRef
17.
Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Wykoff CC, Gatter KC, et al. Dec1 (stra13) protein expression relates to hypoxia-inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J Pathol. 2003;200:222–8.PubMedCrossRef
18.
Shi XH, Zheng Y, Sun Q, Cui J, Liu QH, Qu F, et al. Dec1 nuclear expression: a marker of differentiation grade in hepatocellular carcinoma. World J Gastroenterol. 2011;17:2037–43.PubMedCrossRef
19.
Wang W, Reiser-Erkan C, Michalski CW, Raggi MC, Quan L, Yupei Z, et al. Hypoxia inducible bhlhb2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Biochem Biophys Res Commun. 2010;401:422–8.PubMedCrossRef
20.
Shi X, Zheng Y, Ma W, Wang Y. Possible involvement of DEC1 on the adverse effects of quinolone antibiotics. Toxicology. 2010;271:1–4.PubMedCrossRef
21.
Bhawal UK, Sato F, Arakawa Y, Fujimoto K, Kawamoto T, Tanimoto K, et al. Basic helix–loop–helix transcription factor dec1 negatively regulates cyclin d1. J Pathol. 2011;224:420–9.PubMedCrossRef
22.
Zhang L, Li QQ. Embryo-chondrocyte expressed gene 1, downregulating hypoxia-inducible factor 1alpha, is another marker of lung tumor hypoxia. Acta Pharmacol Sin. 2007;28:549–58.PubMedCrossRef
23.
Wu Y, Sato F, Yamada T, Bhawal UK, Kawamoto T, Fujimoto K, Noshiro M, Seino H, Morohashi S, Hakamada K, Abiko Y, Kato Y, Kijima H: The bhlh transcription factor dec1 plays an important role in the epithelial–mesenchymal transition of pancreatic cancer. International Journal of Oncology 2012
24.
Harbour JW, Dean DC. The rb/e2f pathway: expanding roles and emerging paradigms. Genes Dev. 2000;14:2393–409.PubMedCrossRef
25.
26.
Malumbres M, Barbacid M. Cell cycle, CDKS and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–66.PubMedCrossRef
27.
28.
Sato F, Bhawal UK, Kawamoto T, Fujimoto K, Imaizumi T, Imanaka T, et al. Basic-helix-loop-helix (bhlh) transcription factor dec2 negatively regulates vascular endothelial growth factor expression. Genes Cells: Devoted Molecular Cellular Mech. 2008;13:131–44.CrossRef
29.
Xu Q, Ma P, Hu C, Chen L, Xue L, Wang Z, et al. Overexpression of the dec1 protein induces senescence in vitro and is related to better survival in esophageal squamous cell carcinoma. PLoS One. 2012;7:e41862.PubMedCrossRef
30.
Ming J, Jiang G, Zhang Q, Qiu X, Wang E. Interleukin-7 up-regulates cyclin d1 via activator protein-1 to promote proliferation of cell in lung cancer. Cancer Immunol Immunother. 2012;61:79–88.PubMedCrossRef
31.
Kim JK, Diehl JA. Nuclear cyclin d1: an oncogenic driver in human cancer. J Cell Physiol. 2009;220:292–6.PubMedCrossRef
32.
Rossner MJ, Dorr J, Gass P, Schwab MH, Nave KA. Sharps: mammalian enhancer-of-split- and hairy-related proteins coupled to neuronal stimulation. Mol Cell Neurosci. 1997;10:460–75.PubMedCrossRef
33.
Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A, Lerman MI. Regulation of stra13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the ubc9/ubiquitin proteasome degradation pathway. J Biol Chem. 2001;276:15306–15.PubMedCrossRef
34.
Sun H, Lu B, Li RQ, Flavell RA, Taneja R. Defective t cell activation and autoimmune disorder in stra13-deficient mice. Nat Immunol. 2001;2:1040–7.PubMedCrossRef
35.
Yun Z, Maecker HL, Johnson RS, Giaccia AJ. Inhibition of PPAR gamma 2 gene expression by the hif-1-regulated gene dec1/stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell. 2002;2:331–41.PubMedCrossRef
36.
Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991;350:512–5.PubMedCrossRef
37.
Matsumura I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Albanese C, et al. Transcriptional regulation of the cyclin d1 promoter by stat5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J. 1999;18:1367–77.PubMedCrossRef
Metadata
Title
The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells
Authors
Yang Liu
Liang Wang
Xu-Yong Lin
Jian Wang
Juan-Han Yu
Yuan Miao
En-Hua Wang
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0697-z

Other articles of this Issue 3/2013

Tumor Biology 3/2013 Go to the issue

Research Article

Loss of WIF-1 and Wnt5a expression is related to aggressiveness of sporadic breast cancer in Tunisian patients

Research Article

Overexpression of ARK5 is associated with poor prognosis in hepatocellular carcinoma

Review

Colorectal cancer: a researcher’s perspective of the molecular angel’s gone eccentric in the Vale of Kashmir

Research Article

The association between the poly(A) polymorphism in the VDR gene and cancer risk: a meta-analysis

Research Article

Discussion of modifying stage IV gastric cancer based on Borrmann classification

Research Article

Quantitative assessment of the association between glutathione S-transferase P1 Ile105Val polymorphism and bladder cancer risk
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits